A federal jury in Delaware has awarded Regeneron (NASDAQ:REGN) more than $400M in damages after finding that Amgen ...

A federal jury found Amgen liable for violating antitrust and tort laws. Elsewhere, Allogene and Kyverna trimmed staff and ...

In the long-running feud between Regeneron and Amgen around the companies’ competing PCSK9 cholesterol meds, Regeneron has ...

Morning! Today we start with some breaking newss: Novo Nordisk’s CEO is stepping down. We also discuss a new, tailored CRISPR treatment for an infant with a deadly disease, how Amgen owes Regeneron ...

Shares of Regeneron Pharmaceuticals Inc. REGN advanced 2.39% to $584.99 Thursday, on what proved to be an all-around positive ...

White & Case secures $405M jury win for Regeneron in antitrust case, with Amgen found liable for anti-competitive bundling ...

(Reuters) -A federal jury in Delaware said on Thursday that biotech company Amgen owes competitor Regeneron more than $406 ...

Regeneron Pharmaceuticals won $406.8 million in damages for a lawsuit claiming Amgen violated antitrust and tort laws. A jury in a Delaware court found that Amgen violated certain laws, and gave ...

Shares of Regeneron Pharmaceuticals Inc. slipped 3.63% to $527.78 Friday, on what proved to be an all-around poor trading ...

Regeneron earns a buy rating with strong profit margins, low debt, and growth potential. Discover why shares may see a 39% ...

Adam Kovalčík, 19,receives $100,000 Top Award forhisdevelopment of amedicinethatcan stopviruses from copying genesandcontrolling infectionsat the world’s largest pre-college STEM competition in ...

Regeneron's lead counsel was Jonathan D. Polkes of White & Case LLP.